Dr Xiang-Qun (Sean) Xie (解向群) is a Professor of Pharmaceutical Sciences/Drug Discovery Institute and Associate Dean for Research Innovation at School of Pharmacy, and a PI of an integrated Medicinal Chemistry Biology laboratory of CompuGroup, BioGroup and ChemGroup ( www.CBLigand.org/XieLab) at University of Pittsburgh. He is a charter member of the Science Advisory Board to the United State FDA. He is a Founding Director of CCGS Center ( www.CBLigand.org/CCGS), and a Director/PI of NIH National Center of Excellence for CDAR ( www.CDARCenter.org). Prof Xie and his team are known for their pioneering research for the development of internationally recognized diseases domain-specific chemogenomics knowledgebases, which is an integrated platform of “Big Data to Knowledge” computational chemogenomics-based target identification and system pharmacology for drug discovery translational research. His recent work on Alzheimer’s disease specific chemogenomics database ( www.CBLigand.org/AD/ ) was on 2014 coverpage story of a top peer-reviewed ACS journal. The innovation work includes GPU-accelerated cloud computing TargetHunter© program for drug target identification ( www.CBLigand.org/TargetHunter) (2013 AAPS special theme issue). His lab was the first discovered/patented INK4C-targeting small molecule inhibitors for hematopoietic stem cell expansion (Nature Comm 2015), was the first discovered/patented p62ZZ chemical inhibitors for multiple myeloma (Nature Leukemia 2015), and also reported novel ligands specific to cannabinoid CB2 receptor for osteoporosis and cancers. His invention discovery patents have been successfully licensed out to Biotech/Pharma. He is a recipient of 2014 AAPS Award for Outstanding Research Achievements.
News & Events
New Positions Available
|CBLigand | GDB13 | LICABEDS | UPDDI | PMLSC | PCMLD | UPitt | Links ||